BioNTech to Acquire Biotheus, Enhancing its R&D Capabilities in Oncology and Expanding Reach Across China
Shots:
- The acquisition will enhance BioNTech's capabilities in development, manufacturing & commercialization of next-gen BsAbs & novel therapies in oncology; will expand its reach in China
- Biotheus will get $800M upfront & $150M milestones, with the closing anticipated in Q1’25. It follows a 2023 licensing deal granting BioNTech global rights to BNT327/PM8002 outside Greater China
- BioNTech secures full rights to Biotheus' pipeline, in-house bispecific ADC capability, biologics manufacturing facility & global rights of BNT327 (targets PD-L1 & VEGF-A). BNT327’s potential will be explored with BioNTech’s ADCs; its registrational & combination therapy trials are planned in 2024 & 2025. A P-I/II study of BNT327 + BNT325/DB-1305 for solid tumors began in Jun 2024
Ref: BioNTech | Image: Biotheus
Related News: BioNTech Reports Topline Data from P-II Study of BNT111 to Treat Advanced Melanoma Patients
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
